vs
Side-by-side financial comparison of Federal Realty Investment Trust (FRT) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Federal Realty Investment Trust is the larger business by last-quarter revenue ($336.0M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). Federal Realty Investment Trust runs the higher net margin — 38.6% vs 1.6%, a 37.0% gap on every dollar of revenue. On growth, Federal Realty Investment Trust posted the faster year-over-year revenue change (8.7% vs 5.0%). Over the past eight quarters, Federal Realty Investment Trust's revenue compounded faster (6.5% CAGR vs -0.2%).
Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
FRT vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $336.0M | $177.4M |
| Net Profit | $129.7M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 53.8% | 3.9% |
| Net Margin | 38.6% | 1.6% |
| Revenue YoY | 8.7% | 5.0% |
| Net Profit YoY | 103.5% | — |
| EPS (diluted) | $1.49 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $336.0M | $177.4M | ||
| Q4 25 | $336.0M | $196.9M | ||
| Q3 25 | $322.3M | $179.5M | ||
| Q2 25 | $311.5M | $181.1M | ||
| Q1 25 | $309.2M | $168.9M | ||
| Q4 24 | $311.4M | $187.3M | ||
| Q3 24 | $303.6M | $168.6M | ||
| Q2 24 | $296.1M | $178.0M |
| Q1 26 | $129.7M | $2.9M | ||
| Q4 25 | $129.7M | — | ||
| Q3 25 | $61.6M | $5.4M | ||
| Q2 25 | $155.9M | $-4.8M | ||
| Q1 25 | $63.8M | $4.8M | ||
| Q4 24 | $65.5M | — | ||
| Q3 24 | $61.0M | $-143.5M | ||
| Q2 24 | $112.0M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | 53.8% | 3.9% | ||
| Q4 25 | 53.8% | 1.2% | ||
| Q3 25 | 34.3% | 3.5% | ||
| Q2 25 | 65.1% | 4.7% | ||
| Q1 25 | 35.0% | 1.2% | ||
| Q4 24 | 35.1% | 13.2% | ||
| Q3 24 | 34.9% | -82.8% | ||
| Q2 24 | 53.0% | 15.9% |
| Q1 26 | 38.6% | 1.6% | ||
| Q4 25 | 38.6% | — | ||
| Q3 25 | 19.1% | 3.0% | ||
| Q2 25 | 50.0% | -2.7% | ||
| Q1 25 | 20.6% | 2.8% | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 20.1% | -85.1% | ||
| Q2 24 | 37.8% | 10.6% |
| Q1 26 | $1.49 | $0.07 | ||
| Q4 25 | $1.49 | $0.05 | ||
| Q3 25 | $0.69 | $0.12 | ||
| Q2 25 | $1.78 | $-0.11 | ||
| Q1 25 | $0.72 | $0.10 | ||
| Q4 24 | $0.74 | $0.38 | ||
| Q3 24 | $0.70 | $-3.11 | ||
| Q2 24 | $1.32 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $107.4M | $144.3M |
| Total DebtLower is stronger | $5.0B | — |
| Stockholders' EquityBook value | $3.2B | $653.9M |
| Total Assets | $9.1B | $1.2B |
| Debt / EquityLower = less leverage | 1.53× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $107.4M | $144.3M | ||
| Q4 25 | $107.4M | $238.4M | ||
| Q3 25 | $111.3M | $246.3M | ||
| Q2 25 | $177.0M | $445.9M | ||
| Q1 25 | $109.2M | $493.6M | ||
| Q4 24 | $123.4M | $484.6M | ||
| Q3 24 | $97.0M | $453.8M | ||
| Q2 24 | $103.2M | $404.2M |
| Q1 26 | $5.0B | — | ||
| Q4 25 | $5.0B | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $4.5B | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $3.2B | $653.9M | ||
| Q4 25 | $3.2B | $693.1M | ||
| Q3 25 | $3.2B | $727.2M | ||
| Q2 25 | $3.2B | $757.8M | ||
| Q1 25 | $3.2B | $798.5M | ||
| Q4 24 | $3.2B | $778.3M | ||
| Q3 24 | $3.1B | $749.6M | ||
| Q2 24 | $3.0B | $879.3M |
| Q1 26 | $9.1B | $1.2B | ||
| Q4 25 | $9.1B | $1.3B | ||
| Q3 25 | $8.9B | $1.3B | ||
| Q2 25 | $8.6B | $1.5B | ||
| Q1 25 | $8.6B | $1.6B | ||
| Q4 24 | $8.5B | $1.6B | ||
| Q3 24 | $8.5B | $1.5B | ||
| Q2 24 | $8.4B | $1.6B |
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.53× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 1.42× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FRT
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
